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Abstract 
One of the most important patients-related variables is the patient’s oral health status that predisposes the patient 
to complications during cancer therapy. This especially is the result   of therapy-related variable such as type of 
agents used and the dosage and frequency. Neglected oral health during cancer therapy perpetuates the oral 
complications results in enhanced severity of complications and compromises the therapy and prognosis. Hence 
this paper provides a pathway of multidisciplinary oral management during cancer therapy.   
Keywords: Interceptive therapy; Oral prophylaxis; Salivary substitute; Xerostomia. 
1. Introduction  
Pre-therapy oral management of oncologic patient is usually postponed in situations where the patients were 
gravely ill or the dental treatment would delay oncologic therapy. In such case scenario indicated dental 
treatment hence, by necessity postpone until the patient reaches between courses of oncologic therapy and more 
conveniently post cancer therapy.  
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Under such case scenario it is warranted that patient care must be continued during active phase of cancer 
therapy and manages the immediate adverse effect of cancer therapy. This pathway of management considered 
as an interceptive therapy phase. The aim of the intercept therapy phase is to relieve sensitivity and pain at 
priority, protect remaining oral hard and soft tissue, prescription of appropriate mouth rinses or gel for daily use, 
consultation with oncologic team for further referral. This phase is later taken over by reassessment therapy 
phase. Reassessment period constitute review & monitoring of oral conditions which basically involves diet 
analysis and counselling to control or reduce the effect of aetiological factors, maintenance of oral hygiene 
practices (Figure 1). 
 
Figure1: Oral Management of Patient under Cancer Therapy. 
2. Oral management during cancer therapy 
2.1. Oral hygiene practice 
• A high standard of oral hygiene should be encouraged, including denture hygiene.  
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• Normal daily toothbrushing with a powered or manual soft /supersoft brush should be undertaken, with 
supplemental use of floss or interdental brushes [1]. However, painful mouth often resists daily cleaning 
with a toothbrush. In such situation the oral tissues can be cleaned with oral sponges or gauze moistened 
with alcohol-free chlorhexidine mouthwash.  
• The use of an alcohol free chlorhexidine mouthwash should be recommended if toothbrushing alone is 
inadequate for plaque removal; it can be used in addition or as a short-term alternative to tooth brushing. 
Chlorhexidine is available in concentrations 0.12-0.2% alcohol free preparations and 10ml should be rinsed 
round the mouth for 1 minute/twice daily. The 0.2% concentration may be diluted 1:1 with water if it causes 
mucosal discomfort [2]. 
• The patients receiving radiotherapy prior to bone marrow transplantation often necessitates highly calorific 
and cariogenic food supplements. These patients are at high risk of dental caries and should receive dietary 
advice and fluoride supplements appropriate to their age. For prevention of dental caries the dental team 
should work with the dieticians to manage the length of time for their usage [3-6]. Use sugar free medicines 
wherever possible and rinse the mouth after intake [7]. Adults should use an alcohol free fluoride mouth 
rinse at least once daily (0.05% NaF) at a different time from brushing. They should be prescribed 
5,000ppm fluoride toothpaste for use twice daily. An alternative for adults is 1% sodium fluoride gel or 
0.4% stannous fluoride gel application in custom made trays for ten minutes daily [8]. Children and young 
adults should have fluoride toothpaste, systemic fluoride supplements, application of fluoride varnish and 
fissure sealants and fluoride mouthwashes as appropriate to age [7]. 
• Dentures should be rinsed after meals and cleaned at least once daily by brushing and soaked in 
chlorhexidine mouthwash overnight. An alternative is dilute sodium hypochlorite solution (Milton‘s diluted 
1 in 80) provided there are no metal components. Dentures should not be worn at night.  
2.2. Oral infection prevention  
• Children and adults receiving bone marrow transplants a prophylactic acyclovir dose if there is a high risk 
of viral infections should be undertaken. This is usually prescribed by the oncology team. There is increased 
risk of oral fungal infection in patients receiving chemotherapy and/or radiotherapy [9,10]. Topical agents 
may be preferred to systemic agents due to lower risk of side effects. However because of inconsistent 
results of efficacy of topical agents some advises systemic antifungal agents as preferable.  
• Prosthesis hygiene is very important if there is fungal infection. Miconazole oral gel should be applied to 
the fit surface prior to insertion, provided it is not contraindicated.  
• Every effort is made to reduce the severity of the mucositis. The use of mucosal shields and intensity 
modulated radiotherapy is to be encouraged to decreased severity of mucositis. Intensive oral hygiene, 
correction of poorly fitting dentures or sharp teeth reduces mucositis [11]. Difflam (benzydamine 
hydrochloride mouthwash 15%) reduces the frequency and severity of mucositis and is recommended [12]. 
A regime of 15ml four to eight times daily starting before radiotherapy and continuing during and for two to 
three weeks afterwards is recommended [13]. Topical application of antimicrobial pastes or lozenges shows 
some evidence of reduced severity of ulceration. 
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2.3. Specific recommendations during chemotherapy: 
• Oral cooling for 30 minutes prior to chemotherapy is recommended where mucositis inducing 
chemotherapeutic agents are used (e.g. 5FU). Patients receiving high dose chemotherapy or total body 
irradiation for stem cell transplantation are recommended intravenous keratinocyte growth factor-1 since 
there are promising effects on preventing mucositis [10,11]. 
• Other palliative measure recommended is 2% lidocaine mouthwash used prior to eating [14,15]. 
2.4. Prevention of xerostomia: 
• Parotid gland function can be partially maintained by radiotherapy delivery to affected side [16], 
minimizing the dose of radiotherapy to the parotid glands has shown to improve xerostomia related Quality 
of Life [17-19]. 
• Stimulation by chewing gum may be recommended although there is a limited evidence base [19]. Acidic 
pastilles are not recommended other than for edentulous patients as these may cause tooth erosion and 
sensitivity.  
• For many patients saliva replacement is the only option such as frequent sips of water, or a spray bottle of 
water and using several substitutes.  
• Improvement is only short term. Products may contain fluoride, or electrolytes to reduce demineralisation 
or antibacterial components [20].  
2.5. Reassessment  
The patient should be constantly reassured during this acute phase about the limited period of side effect of 
treatment. Certain food, drinks and mouthwashes, which irritate the oral mucosa, should be avoided to maintain 
oral comfort. Dental treatment is avoided wherever possible during therapy. 
3. Conclusion 
The oncologist must involve the oral health care provider during the initiation of the cancer therapy. The oral 
health care provider must recognize that cancer chemotherapeutics agents are not selective for malignant cells 
and may produce the adverse effects. The oral health care provider must focus on monitoring and minimizing 
these toxicities during cancer therapy. Therefore special care needs to be taken and timing of interventive dental 
treatment should be agreed with the hematologists or the oncology team. 
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